Baxter International Dirección
Dirección controles de criterios 3/4
El CEO de Baxter International's es Joe Almeida , nombrado en Jan 2016, tiene una permanencia de 8.25 años. compensación anual total es $13.79M, compuesta por 9.4% salario y 90.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $23.02M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 4.2 años, respectivamente.
Información clave
Joe Almeida
Chief Executive Officer (CEO)
US$13.8m
Compensación total
| Porcentaje del salario del CEO | 9.4% |
| Permanencia del CEO | 8.4yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 2yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30
Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 05Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price
Apr 24Is Baxter International (NYSE:BAX) Using Too Much Debt?
Apr 03Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 18Investors Could Be Concerned With Baxter International's (NYSE:BAX) Returns On Capital
Feb 10Baxter International: Another YoY Earnings Decline Expected, Shares Tag Support
Feb 03Why Baxter Is One Of My #1 2023 Bets For Healthcare/Medtech
Jan 02An Intrinsic Calculation For Baxter International Inc. (NYSE:BAX) Suggests It's 32% Undervalued
Dec 30Baxter cut to hold at Deutsche Bank on inflation pressures
Dec 15Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Nov 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$38m |
| Dec 31 2023 | US$14m | US$1m | -US$76m |
| Sep 30 2023 | n/a | n/a | US$225m |
| Jun 30 2023 | n/a | n/a | -US$3b |
| Mar 31 2023 | n/a | n/a | -US$3b |
| Dec 31 2022 | US$14m | US$1m | -US$3b |
| Sep 30 2022 | n/a | n/a | -US$3b |
| Jun 30 2022 | n/a | n/a | US$876m |
| Mar 31 2022 | n/a | n/a | US$992m |
| Dec 31 2021 | US$16m | US$1m | US$1b |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$1b |
| Mar 31 2021 | n/a | n/a | US$1b |
| Dec 31 2020 | US$16m | US$1m | US$1b |
| Sep 30 2020 | n/a | n/a | US$911m |
| Jun 30 2020 | n/a | n/a | US$924m |
| Mar 31 2020 | n/a | n/a | US$991m |
| Dec 31 2019 | US$14m | US$1m | US$1b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$16m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$1b |
| Jun 30 2018 | n/a | n/a | US$795m |
| Mar 31 2018 | n/a | n/a | US$840m |
| Dec 31 2017 | US$15m | US$1m | US$609m |
Compensación vs. Mercado: La compensación total ($USD13.79M) de Joe está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: La compensación de Joe ha aumentado mientras la empresa no es rentable.
CEO
Joe Almeida (62 yo)
8.4yrs
Permanencia
US$13,786,671
Compensación
Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 8.4yrs | US$13.79m | 0.11% $ 19.5m | |
| Executive VP & CFO | less than a year | US$5.37m | 0% $ 0 | |
| Executive VP & Group President of Medical Products and Therapies | 1.3yrs | US$4.86m | 0.031% $ 5.5m | |
| Executive VP & Group President of Pharmaceuticals | 1.9yrs | US$3.87m | 0.0016% $ 272.6k | |
| Executive VP & Group President of Kidney Care | less than a year | US$9.64m | 0.0046% $ 798.5k | |
| Senior VP and Chief Medical & Scientific Officer | 1.4yrs | sin datos | sin datos | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Executive VP & General Counsel | 2.2yrs | US$5.66m | 0.0018% $ 318.0k | |
| ?Senior Vice President | no data | sin datos | sin datos | |
| ?Executive VP & Chief Human Resources Officer | 7.1yrs | US$4.14m | 0.037% $ 6.5m | |
| Executive VP & Chief Supply Chain Officer | 4.4yrs | sin datos | 0.0030% $ 522.5k | |
| Executive VP & Group President of Healthcare Systems and Technologies | 2.4yrs | sin datos | 0.021% $ 3.7m |
2.0yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BAX se considera experimentado (2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 8.4yrs | US$13.79m | 0.11% $ 19.5m | |
| Independent Director | less than a year | US$197.82k | 0.0018% $ 311.0k | |
| Chairman Emeritus | 8.4yrs | US$17.88m | sin datos | |
| Independent Director | 2.1yrs | US$349.64k | 0.0026% $ 454.3k | |
| Independent Director | 7.3yrs | US$373.98k | 0.0055% $ 957.5k | |
| Independent Director | 5.3yrs | US$364.98k | 0.0042% $ 732.1k | |
| Independent Director | 2.5yrs | US$363.00k | 0.0028% $ 489.3k | |
| Independent Director | 7.4yrs | US$367.31k | 0.0044% $ 772.3k | |
| Lead Independent Director | 2.1yrs | US$382.31k | 0.0026% $ 454.3k | |
| Independent Director | 3.3yrs | US$357.00k | 0.0032% $ 557.4k | |
| Independent Director | less than a year | US$226.35k | 0.0019% $ 337.2k | |
| Independent Director | 5.3yrs | US$352.98k | sin datos |
4.3yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de BAX se considera experimentada (4.2 años de antigüedad promedio).